Single-Dose CRISPR Therapy Slashes LDL Cholesterol Without Altering DNA
Scribe Therapeutics unveils STX-1150, a liver-targeted epigenetic therapy that durably lowers LDL cholesterol with one dose and no permanent DNA edits.
Summary
Scribe Therapeutics is presenting two major advances at upcoming medical conferences. The first is STX-1150, a therapy that silences the PCSK9 gene in the liver to lower LDL cholesterol — the harmful type linked to heart disease — after just a single dose. Crucially, it does this through epigenetic changes, meaning it adjusts how genes are expressed without permanently altering the DNA itself. The second advance involves next-generation CRISPR tools, including an AI platform called DeepXE that predicts how effectively gene-editing guides will work. Co-founded by CRISPR pioneer Jennifer Doudna and backed by Sanofi and Eli Lilly, Scribe is positioning these technologies as safer, more precise alternatives to traditional gene editing for treating cardiometabolic diseases like high cholesterol.
Detailed Summary
High LDL cholesterol remains one of the most significant and modifiable risk factors for cardiovascular disease, the leading cause of death globally. Current treatments like statins require daily dosing, and while PCSK9 inhibitor drugs are effective, they are expensive and also require repeated administration. Scribe Therapeutics is now presenting preclinical data suggesting a single-dose epigenetic therapy could offer durable LDL control — a potential paradigm shift in cardiovascular prevention.
The lead program, STX-1150, targets the liver and silences the PCSK9 gene using epigenetic mechanisms. PCSK9 is a protein that degrades LDL receptors on liver cells; blocking it allows the liver to clear more LDL from the bloodstream. Unlike traditional gene editing, STX-1150 does not cut or permanently alter DNA — it instead uses epigenetic silencing to suppress PCSK9 expression, which may reduce long-term safety concerns associated with irreversible genomic changes.
Scribe is also showcasing its broader CRISPR engineering platform, including ELXR (Epigenetic Long-Term X-Repressor) and XE (X-Editor) technologies, alongside DeepXE, an AI-powered tool that predicts guide RNA potency. These tools are designed to make CRISPR therapies more specific and effective, reducing off-target effects that have historically been a concern with gene editing approaches.
The company's collaborations with pharmaceutical giants Sanofi and Eli Lilly lend significant credibility and resources to its pipeline. Co-founder Jennifer Doudna, who shared the Nobel Prize for CRISPR discovery, adds further scientific authority to the platform.
However, all data presented are preclinical, meaning results come from laboratory or animal models and have not yet been tested in humans. Durability and safety in human trials remain to be established. Investors and health-conscious observers should monitor upcoming clinical trial announcements before drawing conclusions about real-world applicability.
Key Findings
- STX-1150 lowers LDL cholesterol durably after a single dose by silencing PCSK9 epigenetically, not by cutting DNA.
- Epigenetic silencing avoids permanent DNA alterations, potentially offering a safer profile than traditional gene editing.
- AI platform DeepXE predicts CRISPR guide RNA potency, improving precision and reducing off-target editing risks.
- Scribe is backed by Sanofi and Eli Lilly and co-founded by Nobel laureate Jennifer Doudna.
- All current data are preclinical; human clinical trials have not yet been announced or completed.
Methodology
This is a corporate news report summarizing conference presentations and preclinical data announcements from Scribe Therapeutics. The source, Longevity.Technology, is a credible longevity-focused outlet, but the article is based on company press releases rather than peer-reviewed publications. Evidence basis is preclinical only.
Study Limitations
All data presented are preclinical and have not been validated in human clinical trials, so efficacy and safety in people remain unknown. The article is based on a company press release, introducing potential promotional bias. Durability of epigenetic silencing in humans and long-term off-target effects require independent verification.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.